26th Jan 2026 19:18
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
----------
Orosur Mining Inc - South America-focused minerals explorer and developer - Reports results for the six months ended November 30. Continuing net loss widens to USD4.6 million from USD1.1 million the previous year. Reports no revenue for the period, unchanged. Corporate & administrative expenses increase to USD995,000 from USD913,000. Second-quarter net loss widens to USD3.9 million from USD618,000, and corporate & administrative expenses rise to USD597,000 from USD478,000. Cash totals USD16,280 as of November 30, up from USD4,877 on May 31.
----------
TheraCryf PLC - Cheshire, England-based pharmaceutical firm focused on cancer and brain disorders - Receives notice of allowance from the Canadian Patent Officer for its Orexin-1 addiction programme. Canada "represents the final major market to grant for this intellectual property, completing broad protection across the US, Europe, Canada and key Asian territories", TheraCryf says. The patent provides "the strongest form of patent cover available, conferring long-term exclusivity and significantly strengthening the commercial and partnering proposition for the programme." TheraCryf also reports continued progress on its maximum tolerated dose and dose range finding studies. Says MTD study has seen two species given the regulatory maximum dose with no adverse clinical observations. "This favourable outcome further de-risks the programme and enables progression into repeat-dose DRF studies, the results of which will inform the dosing for the planned 28-day regulatory toxicity studies scheduled in Q1 and Q2 2026, depending on species," TheraCryf says.
----------
Scancell Holdings PLC - Oxford-based pharmaceutical company - Says the US Food & Drug Administration has cleared its investigational new drug application for a registrational phase 3 trial of its iSCIB1+ Immunobody in advanced melanoma. Says progression-free survival is the agreed surrogate endpoint. Adds that it has completed the SCOPE phase 2 open-label, multi-centre study evaluating ImmunoBody immunotherapies SCIB1 and iSCIB1+, in combination with nivolumab plus ipilimumab, in previously untreated unresectable stage IIIB/IV melanoma. Says it has identified a selection marker to enrich the phase 3 trial for responders from analysis of the data, which also demonstrates potentially best-in-class efficacy and durability.
----------
Empiric Student Property PLC - London-based student accommodation provider - Says court has sanctioned scheme of arrangement for acquisition by Unite Group PLC. Expects the acquisition to become effective on Wednesday.
----------
Powerhouse Energy Group PLC - Bingley, England-based firm focused on turning non-recyclable waste into low carbon energy - Signs agreement to lease a 1.98 acre serviced site at Silverwood Business Park, Ballymena, Northern Ireland. Includes an initial rent-free period of up to 12 months, followed by five yearly reviews, and the lease is for a 25-year term. Powerhouse intends to build, own and operate a waste to hydrogen conversion facility at the site, with a capacity of 40 tonnes per day. Says discussions are underway regarding feedstock and offtake agreements. Chief Executive Officer Paul Emmitt says: "This is a major step forward for the company. Ballymena is set to become the hydrogen hub of Northern Ireland, with the organisations including Wrightbus, Translink and the Mid and East Antrim Borough Council all focused on developing the hydrogen economy in Northern Ireland."
----------
Proteome Sciences PLC - London-based life sciences company - Launches UK retail offer of up to 3.4 million new shares at 1.75 pence each, to raise up to GBP60,000. Proteome has also completed a placing of 29.4 million shares and a subscription for 18.6 million at the same price, to raise up to GBP840,000. Subscription is by "major shareholder" Vulpes Life Science Fund and Chief Commercial Officer Richard Dennis. Says net proceeds will be used to fund various workstreams, including launching an innovative new range of DXT isotopic plex tags and introducing novel 'Solvent Shift' chemoproteomic workflows.
----------
By Emma Curzon, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Orosur MiningTheracryf PLCScancell HoldingsEmpiricPowerhouse EnerProteome